Загрузка...
Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
PURPOSE: Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor ty...
Сохранить в:
| Опубликовано в: : | Cancer Chemother Pharmacol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188725/ https://ncbi.nlm.nih.gov/pubmed/32314030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04073-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|